Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial is a research paper published in Neuro-Oncology (2020). On theSindex it has a DataRank of 0.505. It has been cited 28 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.505
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: U10CA180820
National Cancer Institute
Grant: U10CA180794
National Cancer Institute
Grant: U01 CA176110
National Cancer Institute
Grant: R01CA082500
NCI NIH HHS
Grant: R01 CA255123
NCI NIH HHS
Grant: P30 CA014236
National Institutes of Health
Grant: 3U10CA180820-02S3
ECOG-ACRIN Operations Center
National Institutes of Health
Grant: 2R01CA082500-13
MRI Contrast Agent Methods to Assess Tumor Angiogenesis
National Institutes of Health
Grant: 5U01CA176110-03
Quantitative (Perfusion and Diffusion) MRI Biomarkers to Measure Glioma Response
National Institutes of Health
Grant: 5U10CA180794-04
ECOG-ACRIN Network Group Statistics and Data Management Center
National Institutes of Health
FWCI
2.02
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals